Experimental cancer drug PTX-100 enters early human testing
Disease control
Completed
This early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five day…
Phase: PHASE1 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:35 UTC